Navigation Links
Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes

CINCINNATI, June 17, 2011 /PRNewswire/ -- Kendle International Inc. (Nasdaq: KNDL) ("Kendle"), announced today that it has increased the consideration amount offered for its cash tender offer and consent solicitation for any and all of its $142.5 million aggregate principal amount of outstanding 3.375% Convertible Senior Notes due 2012 (CUSIP No. 48880LAA5; ISIN No. US48880LAA52) (the "Notes").  The consideration for each $1,000.00 principal amount of Notes validly tendered and not validly withdrawn pursuant to the tender offer and consent solicitation was increased from $1,000.00 to $1,002.50, plus accrued and unpaid interest to, but not including, the payment date, which is expected to be promptly after the expiration date.  The tender offer and consent solicitation is being conducted in connection with the previously announced agreement of Kendle to be merged with Triangle Two Acquisition Corp., an Ohio corporation and newly formed subsidiary of INC Research, LLC, a Delaware limited liability company ("INC") (the "Merger").  Completion of the tender offer and consent solicitation is not a condition to completion of the Merger.  However, the tender offer and consent solicitation is itself subject to the satisfaction of certain conditions, including the satisfaction of the conditions precedent to the Merger as set forth in the Agreement and Plan of Merger dated as of May 4, 2011 by and among Kendle, INC and Triangle Two Acquisition Corp. and the receipt of consents of the noteholders representing a majority of the outstanding principal amount of the notes.  

The tender offer and consent solicitation with respect to the Notes will expire at 8:00 am, New York City time, on July 6, 2011, unless extended or earlier terminated by Kendle.  If Kendle makes a material change in the terms of the offer or consent solicitation or the information concerning the offer or consent solicitation, it will then disseminate additional offering materials and extend the offer or, if applicable, consent solicitation, to the extent required by law.

Holders tendering their Notes will be required to consent to the proposed amendment to the indenture governing the Notes, which would eliminate the reporting covenant in the indenture.  The tender offer and consent solicitation is being made pursuant to the terms and conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated June 6, 2011 for the Notes and the related Letter of Transmittal and Consent (both as amended in the Schedule TO/A that Kendle filed today (the "Schedule TO/A") with the U.S. Securities and Exchange Commission (the "SEC") and together, the "Offer Documents").

Kendle has retained Morgan Stanley & Co. LLC ("Morgan Stanley") to act as dealer manager in connection with the tender offer and consent solicitation.  Questions about the tender offer and consent solicitation may be directed to Morgan Stanley at (800) 624–1808 (toll free) or (212) 761–1941 (collect).  Copies of the Offer Documents and other related documents may be obtained from Global Bondholder Services Corporation, the information agent for the tender offer and consent solicitation, at (866) 470−4300 (toll free) or (212) 430−3774 (for banks and brokers only).

The tender offer and consent solicitation is being made solely pursuant to the applicable Offer Documents, which set forth the complete terms of the tender offer and consent solicitation.  Holders should also read the Schedule TO, filed on June 6, 2011, and the Schedule TO/A.  Under no circumstances shall this press release constitute an offer to purchase or the solicitation of an offer to sell the Notes or any other Kendle securities.  This press release also is not a solicitation of consents to the proposed amendment to the indenture.  No recommendation is made as to whether holders of the securities should tender their securities or give their consent.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offering, solicitation or sale would be unlawful.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Kendle's focus is on innovative solutions that reduce cycle times for its customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, Kendle offers experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet its customers' clinical development challenges. For more information, please visit.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements relating to the proposed Merger between Kendle and INC, as defined above, and the expected timing and completion of the transaction. Words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions are intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of Kendle's management and involve a number of significant risks and uncertainties, many of which are difficult to predict and are generally beyond the control of Kendle. Actual results may differ materially from the results anticipated in these forward-looking statements. There can be no assurance as to the timing of the closing of the transaction, or whether the transaction will close at all. The following factors, among others, could cause or contribute to such material differences: the ability to obtain the approval of the transaction by Kendle's shareholders; the ability to obtain required regulatory approvals of the transaction or to satisfy other conditions to the transaction on the terms and expected timeframe or at all; transaction costs; economic conditions; a material adverse change in the business, assets, financial condition or results of operations of Kendle; and the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers or other business partners. Additional factors that could cause Kendle's results to differ materially from those described in the forward-looking statements can be found in the periodic reports filed with the Securities and Exchange Commission and in the proxy statement Kendle has filed with the Securities and Exchange Commission and mailed to its shareholders with respect to the proposed transaction, which are or will be available at the Securities and Exchange Commission's web site ( at no charge. Kendle assumes no responsibility to update any forward-looking statements as a result of new information or future developments except as expressly required by law.  All subsequent written and oral forward-looking statements attributable to Kendle, or persons acting on Kendle's behalf, are expressly qualified in their entirety by these cautionary statements.

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the UBS Global Life Sciences Conference
2. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
3. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
4. Kendle Named a Best Place to Work in Greater Cincinnati
5. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
6. Kendle to Present at the 2008 Credit Suisse Health Care Conference
7. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
8. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
9. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
10. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
11. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
Post Your Comments:
(Date:10/13/2015)... ... 2015 , ... SonaCare Medical, LLC, a pioneer in minimally ... novo clearance from the U.S. Food and Drug Administration (FDA) to market the ... is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory ...
(Date:10/13/2015)... ... October 13, 2015 , ... The ... school age children in the areas of Science, Technology, Engineering and Mathematics. The ... national economy, and the program aims to increase the number of students who ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen ... presented additional findings from an exploratory sub-study of the previously ... presented today in an oral plenary session at the American ... in Seattle . 2 ... The small exploratory sub-study data showed that, at month 12, ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
Breaking Biology Technology:
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:9/30/2015)... 2015  The global glucose monitoring device and diabetes management ... a new report on the industry from Kalorama Information. Sales in ... market, followed by continuous glucose monitoring and sensor segment, according ... for these products in its latest report, The Global ... , ...
(Date:9/28/2015)... 28, 2015 The global ... USD 12.03 billion by 2020, growing at a CAGR ... as Backside Illumination (BSI) technique to improve picture quality ... period.      (Logo: , ... to reduce loss and, thus, reduce the noise interference ...
Breaking Biology News(10 mins):